Loading your page…
Loading your page…
Published by American Venous Forum and American Venous and Lymphatic Society
This position statement, endorsed by the American Venous Forum (AVF) and the American Venous and Lymphatic Society (AVLS), assesses the clinical utility of non-pneumatic compression devices (NPCDs) in managing lymphedema and phlebolymphedema. NPCDs use shape-memory alloys (nitinol) to deliver programmable sequential gradient compression while enabling patient mobility. The statement reviews clinical evidence, including two randomized controlled trials (NILE and TEAYS) which show NPCD's superiority over advanced pneumatic compression devices (PCDs) regarding volume reduction, quality of life, and treatment adherence.
Key Takeaways
Treating chronic venous insufficiency (CVI) (CEAP C3-C6) as lymphedema to improve management outcomes.
Non-pneumatic compression (NPCD) should be considered after conservative treatment failure and included in future guideline assessments.
Clinical Topic
Lymphedema and phlebolymphedema management using non-pneumatic compression devices (NPCDs)
Objectives
To review and evaluate the clinical evidence, design, mechanisms of action, and clinical utility of non-pneumatic compression devices (NPCDs) in the management of lymphedema and phlebolymphedema.
Target Patient Population
Patients with lymphedema, phlebolymphedema, chronic venous insufficiency (CVI), lipedema, or chronic edema-related conditions.
Target Providers
Therapeutic Area
Vascular and Lymphatic DiseasesGuideline Scope
Inclusion Criteria
Exclusion Criteria
Care Settings
Special Populations
Contraindications
Monitoring Guidance
Monitor for localized skin irritation and patient compliance; evaluate benefit in patients with impaired ambulation.
Difficulty
intermediate
Learning Paths